At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 32 enrolled
Drug / intervention
Triptorelin pamoate 15mgdrug
Likely dose
Triptorelin pamoate 15mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Multicentre, Single Arm Study to Assess the Efficacy and Safety of Triptorelin 3-month Formulation in Chinese Children With Central Precocious Puberty
In Brief
A Phase 3 clinical trial evaluating Triptorelin pamoate 15mg for Central Precocious Puberty. Completed, enrolled 32 participants across 7 sites.
Detailed Summary
The purpose of this research was to confirm the effectiveness and safety of the study drug, Triptorelin pamoate 15mg 3-month formulation, in a Chinese population of Central Precocious Puberty (CPP) children.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCentral Precocious Puberty
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedFeb 2021
Enrollment StartMar 2021
Primary CompletionFeb 2022
Study CompletionSep 2022
TodayJul 2026
First PostedFeb 3, 2021
Enrollment StartMar 27, 2021
Primary CompletionFeb 9, 2022
Study CompletionSep 3, 2022
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 5.4 years ago
Interventions
Triptorelin pamoate 15mgdrug
Intramuscular injection (IM)